BRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020

Reuters2023-02-06

Feb 6 (Reuters) - Merck & Co Inc :

* NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK & CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020

* NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S EXCLUSIVE LICENSE TO DISTRIBUTE, COMMERCIALIZE SIVEXTRO WAS CONVERTED TO NON-EXCLUSIVE LICENSE

* NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S UNIT AND MERCK'S 2 UNITS AGREED TO TERMINATE DISTRIBUTION AGREEMENT, EFFECTIVE JUNE 30

* NABRIVA THERAPEUTICS - COMPANY NO LONGER INTENDS TO ACTIVELY PROMOTE SIVEXTRO

* NABRIVA THERAPEUTICS - EXPECTS TO CONTINUE TO MAKE SIVEXTRO AVAILABLE TO WHOLESALE CUSTOMERS & RECORD REVENUE ON ACCOUNT OF ANY SALES UNTIL JUNE 30

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2309362851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-02-06 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2309362851","market":"us","top_or_hot":-1,"title":"BRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020","media":"Reuters","content":"<html><body><p>Feb 6 (Reuters) - Merck &amp; Co Inc   :</p><p>   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK &amp; CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020</p><p>   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S EXCLUSIVE LICENSE TO DISTRIBUTE, COMMERCIALIZE SIVEXTRO WAS CONVERTED TO NON-EXCLUSIVE LICENSE</p><p>   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S UNIT AND MERCK'S 2 UNITS AGREED TO TERMINATE DISTRIBUTION AGREEMENT, EFFECTIVE JUNE 30</p><p>   * NABRIVA THERAPEUTICS - COMPANY NO LONGER INTENDS TO ACTIVELY PROMOTE SIVEXTRO</p><p>   * NABRIVA THERAPEUTICS - EXPECTS TO CONTINUE TO MAKE SIVEXTRO AVAILABLE TO WHOLESALE CUSTOMERS &amp; RECORD REVENUE ON ACCOUNT OF ANY SALES UNTIL JUNE 30</p><p>Further company coverage:   </p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-06 19:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 6 (Reuters) - Merck & Co Inc   :   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK & CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020   * ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989772923.USD","symbol_name":"CPR Invest - Climate Action A2 Acc USD-H","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2309362851","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2309362851","pubTimestamp":1675682097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 6 (Reuters) - Merck & Co Inc   :   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","MRK":"默沙东","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4559":"巴菲特持仓","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4550":"红杉资本持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","BK4585":"ETF&股票定投概念","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0861579265.USD":"联博低波幅策略股票基金A","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4534":"瑞士信贷持仓","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4516":"特朗普概念","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD"},"translate_title":"简介——Nabriva Therapeutics——1月31日，Co的部门与Merck&Co的两个部门就2020年7月15日的分销协议签订了书面协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNT":1,"MRK":1,"NBRV":0.9},"content_text":"Feb 6 (Reuters) - Merck & Co Inc   :   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK & CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S EXCLUSIVE LICENSE TO DISTRIBUTE, COMMERCIALIZE SIVEXTRO WAS CONVERTED TO NON-EXCLUSIVE LICENSE   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S UNIT AND MERCK'S 2 UNITS AGREED TO TERMINATE DISTRIBUTION AGREEMENT, EFFECTIVE JUNE 30   * NABRIVA THERAPEUTICS - COMPANY NO LONGER INTENDS TO ACTIVELY PROMOTE SIVEXTRO   * NABRIVA THERAPEUTICS - EXPECTS TO CONTINUE TO MAKE SIVEXTRO AVAILABLE TO WHOLESALE CUSTOMERS & RECORD REVENUE ON ACCOUNT OF ANY SALES UNTIL JUNE 30Further company coverage:   ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2309362851"}